INmune Bio (INMB) Stock Price, News & Analysis

Company Overview

INmune Bio, Inc. is a clinical-stage biotechnology company focused on developing treatments that harness and modulate the innate immune system. The company’s research is aimed at addressing diseases in which chronic inflammation or impaired immune function plays a significant role, including cancer, neurodegenerative disorders and certain psychiatric conditions.

Its lead product candidate is XPro, a next-generation tumor necrosis factor inhibitor designed to selectively neutralize soluble TNF while preserving transmembrane TNF signaling. INmune Bio has investigated XPro in areas including Alzheimer’s disease and treatment-resistant depression, as well as other conditions associated with neuroinflammation. The company also operates the INKmune platform, which is intended to activate and expand a patient’s own natural killer cells for potential use in cancer immunotherapy.

INmune Bio was founded in 2015 and is headquartered in Boca Raton, Florida. The company is led by Raymond J. Tesi, M.D., who serves as chief executive officer and has a background in medicine, immunology and biotechnology. Its development programs are conducted through clinical and research collaborations in the United States and other regions.

Key Stats

• Today's Range: $1.30 to $1.42
• 50-Day Range: $1.38 to $2.51
• 52-Week Range: $1.09 to $2.60
• Volume: 235,721 shs
• Average Volume: 482,101 shs
• Market Capitalization: $36.64 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Moderate Buy

INmune Bio Stock Analysis - MarketRank™

INmune Bio scored higher than 10% of companies evaluated by MarketBeat, and ranked 861st out of 901 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

INmune Bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 strong buy rating, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

INmune Bio has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of INmune Bio is -1.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of INmune Bio is -1.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

INmune Bio has a P/B Ratio of 1.50. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

13.23% of the float of INmune Bio has been sold short.

Short Interest Ratio / Days to Cover

INmune Bio has a short interest ratio ("days to cover") of 8.25.

Change versus previous month

Short interest in INmune Bio has recently increased by 8.61%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

INmune Bio does not currently pay a dividend.

Dividend Growth

INmune Bio does not have a long track record of dividend growth.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.46

News Sentiment

INmune Bio has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for INmune Bio this week, compared to 2 articles on an average week.

MarketBeat Follows

2 people have added INmune Bio to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 0.9 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, INmune Bio insiders have not sold or bought any company stock.

Percentage Held by Insiders

21.40% of the stock of INmune Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

12.72% of the stock of INmune Bio is held by institutions.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 11/03/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:INMB
• CIK: 1711754
• Web: www.inmunebio.com
• Phone: (858) 964-3720
• Fax: N/A
• Employees: 21
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.67)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$45.93 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -82.87%
• Return on Assets: -62.23%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.04
• Quick Ratio: 4.04

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.88 per share
• Price / Book: 1.50

Miscellaneous

• Outstanding Shares: 27,754,000
• Free Float: 21,976,000
• Market Cap: $36.64 million
• Optionable: Optionable
• Beta: 0.89